Phase 3
N=42
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
Post-surgical Cystoid Macular Edema (PSCME)
Bottom Line
View on ClinicalTrials.gov: NCT01769352 ↗Enrolled (actual)
42
Serious AEs
21.4%
Results posted
Sep 2017
Primary outcome: Primary: Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline — 10.6; 7.8; 13.1; 9.4 letters
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- PredA + Kelac (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Johns Hopkins University
- Primary completion
- Apr 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline |
10.6; 7.8; 13.1; 9.4 | — |
| SECONDARY Mean Change in Central Subfield Thickness at Week 12 From Baseline |
-152.7; -56.4; -25.9; -75.0 | — |
| SECONDARY Mean Change in Intraocular Pressure at Week 12 From Baseline |
2.6; 3.3; 0.3; 1.5 | — |
| SECONDARY Mean Change in Best-Corrected Visual Acuity Between Week 12 and Week 48 |
9.3; 5.4; 10.8 | — |
| SECONDARY Mean Change in Central Subfield Thickness (CST) Between Week 12 and Week 48 |
-109.7; -44.0; -1.3 | — |
| SECONDARY Mean Change in Intraocular Pressure Between Week 12 and Week 24 |
2.3; 0.0; -4.7 | — |
Summary
The purpose of this study is to compare the change in visual acuity of patients with post surgical cystoid macular edema who will be treated with two different regimens.
Eligibility Criteria
Inclusion Criteria
- Age more than or equal to 18 years
- Diagnosis of PSCME in study eye confirmed by FA showing leakage from retinal vessels resulting in pooling of dye in the fovea and Spectralis SD-OCT showing intraretinal fluid in or around the fovea.
- BCVA score in the study eye of 20/30 to 20/400 inclusive (Snellen equivalents using the ETDRS protocol at a distance of 4 meters).
- In the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from PSCME and not to any other reason.
Exclusion Criteria
- Any patient who has other retinal diseases known to cause macular edema (choroidal neovascularization, vein occlusion, diabetic macular edema in the study eye). Patients with nonexudative Age Related Macular Degeneration (ARMD) or non-proliferative diabetic retinopathy without macular edema can be included in the study.
- Other reason for decreased visual acuity (such as amblyopia, foveal atrophy, optic atrophy).
- Pre-existing diagnosis of glaucoma in the study eye
- Inability to comply with study or follow up procedures
- Pregnancy (Women of child bearing age will be asked to take a urine pregnancy test prior to enrolling in the study).
Data sourced from ClinicalTrials.gov (NCT01769352). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.